Lipoprotein(a) and cardiovascular disease
Open Access
- 20 September 2024
- journal article
- review article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 481 (19) , 1277-1296
Abstract
Elevated plasma levels of lipoprotein(a) (Lp(a)) are a prevalent, independent, and causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease. Lp(a) consists of a lipoprotein particle resembling low density lipoprotein and the covalently-attached glycoprotein apolipoprotein(a) (apo(a)). Novel therapeutics that specifically and potently lower Lp(a) levels are currently in advanced stages of clinical development, including in large, phase 3 cardiovascular outcomes trials. However, fundamental unanswered questions remain concerning some key aspects of Lp(a) biosynthesis and catabolism as well as the true pathogenic mechanisms of the particle. In this review, we describe the salient biochemical features of Lp(a) and apo(a) and how they underlie the disease-causing potential of Lp(a), the factors that determine plasma Lp(a) concentrations, and the mechanism of action of Lp(a)-lowering drugs.Keywords
This publication has 163 references indexed in Scilit:
- Therapeutic Potential of Lipoprotein(a) InhibitorsDrugs, 2024
- Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) FormationJAMA, 2023
- Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable HypothesisCurrent Atherosclerosis Reports, 2020
- Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic StenosisCardiovascular Drugs and Therapy, 2016
- Heterogeneity of peptide adducts with carbonylated lipid peroxidation productsJournal of Mass Spectrometry, 2015
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular MortalityJAMA, 2009
- Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial InfarctionJAMA, 2009
- Apolipoprotein(a): A Puzzling Evolutionary StoryJournal of Molecular Evolution, 1997
- Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor‐related protein/α2‐macroglobulin receptorFEBS Letters, 1993
- Solution structure of the kringle 4 domain from human plasminogen by 1H nuclear magnetic resonance spectroscopy and distance geometryJournal of Molecular Biology, 1990